Differential activity-dependent development of corticospinal control of movement and final limb position during visually guided locomotion.
Although we understand that activity- and use-dependent processes are important in determining corticospinal axon terminal development in the spinal cord, little is known about the role of these processes in development of skilled control of limb movements. In the present study we determined the effects of unilateral motor cortex activity blockade produced by muscimol infusion during the corticospinal axon terminal refinement period, between postnatal weeks 5-7, on visually guided locomotion. We examined stepping and forepaw placement on the rungs of a horizontal ladder and gait modifications as animals stepped over obstacles during treadmill walking. When cats traversed the horizontal ladder, the limb contralateral to inactivation was placed significantly farther forward on the rungs than the ipsilateral limb, indicating defective endpoint control. Similarly, when animals stepped over obstacles on a treadmill, the contralateral limb was placed farther in front of the obstacle, but only when it was the first (i.e., leading) limb to step over the obstacle, not when it was the second (i.e., trailing) limb. This is also indicative of an endpoint control deficit. In contrast, neither during ladder walking, nor when stepping over obstacles on the treadmill, was there any consistent evidence for a major impairment in limb trajectory. These results point to distinct and possibility independent corticospinal mechanisms for movement trajectory control and endpoint control. Although corticospinal activity during early postnatal development is needed to refine circuits for accurate endpoint control, this activity-dependent refinement is not needed for movement trajectory control.
Friel
K M
KM
Center for Neurobiology and Behavior, Columbia University, New York, NY 10032, USA.
Drew
T
T
Martin
J H
JH
D000704:Analysis of Variance; D000818:Animals; D000831:Animals, Newborn; D001285:Atropine / Q000494:pharmacology; D001522:Behavior, Animal; D001696:Biomechanical Phenomena; D002415:Cats; D003423:Critical Period, Psychological; D005121:Extremities / Q000254:growth & development / Q000294:innervation*; D007839:Functional Laterality; D018755:GABA Agonists / Q000494:pharmacology; D008124:Locomotion / Q000502:physiology*; D009043:Motor Activity / Q000502:physiology*; D009044:Motor Cortex / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism; D018727:Muscarinic Antagonists / Q000494:pharmacology; D009118:Muscimol / Q000494:pharmacology; D016900:Neurofilament Proteins / Q000378:metabolism; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology*; D011712:Pyramidal Tracts / Q000187:drug effects / Q000254:growth & development / Q000502:physiology*; D014785:Vision, Ocular / Q000187:drug effects / Q000502:physiology*
D018755:GABA Agonists; D018727:Muscarinic Antagonists; D016900:Neurofilament Proteins; D009118:Muscimol; D001285:Atropine